Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

FORT GORDON, Ga.–During Cyber Quest 25, 75th U.S. Army Reserve Innovation Command Soldiers partnered with formerly Army ...

AI-driven cost cuts accelerate as Vista and Meta slash roles, signaling a broader structural shift across tech and private ...